{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-029557","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.057370+00:00","generated_at":"2026-06-23T23:43:41.957039+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Galectin Therapeutics Q2 2022 net loss $9.7M; secures $60M credit line; trial enrollment 230 patients randomized","bullets":["Net loss applicable to common stockholders of $9.7M ($0.16/shr) vs $8.5M ($0.15/shr) in Q2 2021.","R&D expenses rose to $8.1M from $6.5M, driven by NAVIGATE trial costs.","Cash and equivalents $24.2M as of June 30, 2022; $60M line of credit from Richard Uihlein available.","NAVIGATE trial: 230 patients randomized, 70 in screening; enrollment expected to complete Q4 2022.","Planning to file IND with FDA for belapectin plus Keytruda in head and neck cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-029557","json":"https://secwatch.observer/filing/0001140361-22-029557.json","markdown":"https://secwatch.observer/filing/0001140361-22-029557.md","text":"https://secwatch.observer/filing/0001140361-22-029557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122029557/0001140361-22-029557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122029557/brhc10040754_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:43:41.957039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}